| Trial ID: | L4624 |
| Source ID: | NCT00333723
|
| Associated Drug: |
Rosiglitazone
|
| Title: |
AVANDIA With Glyburide In African American And Hispanic Patients With Type 2 Diabetes Not Controlled by Glyburide Alone
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: Rosiglitazone
|
| Outcome Measures: |
Primary: Efficacy of rosiglitazone combined with glyburide to glyburide monotherapy in reducing glycosylated hemoglobin (HbA1c)., 24 Weeks | Secondary: Efficacy of rosiglitazone combined with glyburide to glyburide monotherapy upon FPG, c-peptide, HOMA and responder rates., 24 Weeks
|
| Sponsor/Collaborators: |
Sponsor: GlaxoSmithKline
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
245
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: TREATMENT
|
| Start Date: |
2000-07-28
|
| Completion Date: |
2003-01-06
|
| Results First Posted: |
|
| Last Update Posted: |
2017-10-09
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT00333723
|
